Immunopathogenesis of accelerated allograft rejection in sensitized recipients: Humoral and nonhumoral mechanisms

被引:28
作者
Hancock, WW
Gao, W
Shemmeri, N
Shen, XD
Gao, F
Busuttil, RW
Zhai, Y
Kupiec-Weglinski, JW
机构
[1] Millennium Pharmaceut Inc, Transplantat, Cambridge, MA 02139 USA
[2] Univ Calif Los Angeles, Dept Surg, Dumont UCLA Transplant Ctr, Los Angeles, CA 90095 USA
关键词
D O I
10.1097/00007890-200205150-00006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction. Accelerated rejection (AccR) in sensitized recipients (second-set rejection) is considered a classic humorally mediated form of allograft rejection, although additional effector mechanisms may be involved. Methods. We developed a model of AccR in which C57BL6 mice are sensitized by BALB/c skin grafts, followed 10 days later by transplantation of BALB/c hearts. We undertook analysis of various humoral and cellular components in this model using knockout or monoclonal antibody-treated allograft recipients. Results. Sensitized mice rejected cardiac allografts in 34+/-7 hr. AccR was accompanied by endothelial deposition of immunoglobulins, complement, and fibrin, but also by dense expression of multiple chemokines and a mixed polymorphonuclear and mononuclear cellular infiltrate. Whereas neutrophil or complement depletion had no significant effect on the tempo of AccR, surprisingly B cell-deficient recipients still underwent AccR (41+/-7 hr) in conjunction with T cell and macrophage recruitment. In contrast, T cell-deficient (nude) mice maintained functioning cardiac allografts for >720 hr despite prior skin engraftment. Conclusions. AccR in sensitized experimental recipients involves multiple effector pathways. Although most previous studies have emphasized the key role of humoral pathways in mediating AccR, our data indicate that T cell-dependent mechanisms can also promote AccR, alone or in conjunction with humoral responses.
引用
收藏
页码:1392 / 1397
页数:6
相关论文
共 20 条
[1]   ENDOTHELIAL-CELL ACTIVATION AND THROMBOREGULATION DURING XENOGRAFT REJECTION [J].
BACH, FH ;
ROBSON, SC ;
FERRAN, C ;
WINKLER, H ;
MILLAN, MT ;
STUHLMEIER, KM ;
VANHOVE, B ;
BLAKELY, ML ;
VANDERWERF, WJ ;
HOFER, E ;
DEMARTIN, R ;
HANCOCK, WW .
IMMUNOLOGICAL REVIEWS, 1994, 141 :5-30
[2]   ACTIVATION OF INTRAGRAFT ENDOTHELIAL AND MONONUCLEAR-CELLS DURING DISCORDANT XENOGRAFT REJECTION [J].
BLAKELY, ML ;
VANDERWERF, WJ ;
BERNDT, MC ;
DALMASSO, AP ;
BACH, FH ;
HANCOCK, WW .
TRANSPLANTATION, 1994, 58 (10) :1059-1066
[3]   Effect of repetitive high-dose treatment with soluble complement receptor type 1 and cobra venom factor on discordant xenograft survival [J].
Candinas, D ;
Lesnikoski, BA ;
Robson, SC ;
Miyatake, T ;
Scesney, SM ;
Marsh, HC ;
Ryan, US ;
Dalmasso, AP ;
Hancock, WW ;
Bach, FH .
TRANSPLANTATION, 1996, 62 (03) :336-342
[4]   T cell independence of macrophage and natural killer cell infiltration, cytokine production, and endothelial activation during delayed xenograft rejection [J].
Candinas, D ;
Belliveau, S ;
Koyamada, N ;
Miyatake, T ;
Hechenleitner, P ;
Mark, W ;
Bach, FH ;
Hancock, WW .
TRANSPLANTATION, 1996, 62 (12) :1920-1927
[5]   SINGLE-STEP METHOD OF RNA ISOLATION BY ACID GUANIDINIUM THIOCYANATE PHENOL CHLOROFORM EXTRACTION [J].
CHOMCZYNSKI, P ;
SACCHI, N .
ANALYTICAL BIOCHEMISTRY, 1987, 162 (01) :156-159
[6]   Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection [J].
Gao, W ;
Topham, PS ;
King, JA ;
Smiley, ST ;
Csizmadia, V ;
Lu, B ;
Gerard, CJ ;
Hancock, WW .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (01) :35-44
[7]   Targeted disruption of the beta-chemokine receptor CCR1 protects against pancreatitis-associated lung injury [J].
Gerard, C ;
Frossard, JL ;
Bhatia, M ;
Saluja, A ;
Gerard, NP ;
Lu, B ;
Steer, M .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (08) :2022-2027
[8]   Chemokines and their receptors in allograft rejection [J].
Hancock, WW ;
Gao, W ;
Faia, KL ;
Csizmadia, V .
CURRENT OPINION IN IMMUNOLOGY, 2000, 12 (05) :511-516
[9]   CYCLOSPORINE AND ANTI-INTERLEUKIN-2 RECEPTOR MONOCLONAL-ANTIBODY THERAPY SUPPRESS ACCELERATED REJECTION OF RAT CARDIAC ALLOGRAFTS THROUGH DIFFERENT EFFECTOR MECHANISMS [J].
HANCOCK, WW ;
DISTEFANO, R ;
BRAUN, P ;
SCHWEIZER, RT ;
TILNEY, NL ;
KUPIECWEGLINSKI, JW .
TRANSPLANTATION, 1990, 49 (02) :416-421
[10]   Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection [J].
Hancock, WW ;
Sayegh, MH ;
Zheng, XG ;
Peach, R ;
Linsley, PS ;
Turka, LA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (24) :13967-13972